Ratings by Roth/MKM (Tony Butler)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 11/15/2022 | Humanigen | HGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 11/4/2022 | NextCure Inc. | NXTC | Maintain | Neutral (N/A) |
|
Details | ||
| 10/27/2022 | Aravive Inc. | ARAV | Maintain | Buy (N/A) |
|
Details | ||
| 10/20/2022 | Ayala Pharmaceuticals | AYLA | Downgrade | Sell (Buy) |
0.91 (0.50) |
-45.05% | Details | |
| 9/9/2022 | Adaptimmune Therapeutics plc | ADAP | Maintain | Buy (N/A) |
|
Details | ||
| 8/11/2022 | GT Biopharma Inc. | GTBP | Downgrade | Neutral (Buy) |
2.87 (2.86) |
-0.35% | Details | |
| 8/3/2022 | G1 Therapeutics | GTHX | Maintain | Buy (N/A) |
|
Details | ||
| 7/13/2022 | Humanigen | HGEN | Downgrade | Neutral (Buy) |
2.99 (0.04) |
-98.66% | Details | |
| 7/13/2022 | Atara Biotherapeutics | ATRA | Maintain | Buy (N/A) |
|
Details | ||
| 6/3/2022 | Aravive Inc. | ARAV | New Coverage | Buy (N/A) |
1.22 (0.04) |
-96.72% | Details | |
| 6/2/2022 | Rain Therapeutics | RAIN | New Coverage | Buy (N/A) |
2.32 (9.68) |
317.24% | Details | |
| 5/6/2022 | NextCure Inc. | NXTC | Maintain | Neutral (N/A) |
|
Details | ||
| 5/4/2022 | G1 Therapeutics | GTHX | Maintain | Buy (N/A) |
|
Details | ||
| 5/2/2022 | Genenta Science S.p.A. | GNTA | Maintain | Buy (N/A) |
|
Details | ||
| 3/29/2022 | Ayala Pharmaceuticals | AYLA | Maintain | Buy (N/A) |
|
Details | ||
| 2/22/2022 | Humanigen | HGEN | Maintain | Buy (N/A) |
|
Details | ||
| 2/17/2022 | Marker Therapeutics | MRKR | Downgrade | Neutral (Buy) |
0.59 (1.38) |
133.9% | Details | |
| 11/19/2021 | Compass Therapeutics | CMPX | New Coverage | Buy (N/A) |
3.87 (5.51) |
42.38% | Details | |
| 11/5/2021 | Fate Therapeutics | FATE | Maintain | Neutral (N/A) |
|
Details | ||
| 11/3/2021 | G1 Therapeutics | GTHX | Maintain | Buy (N/A) |
|
Details | ||
| 10/7/2021 | Bicycle Therapeutics | BCYC | Maintain | Buy (N/A) |
|
Details | ||
| 10/7/2021 | Merus N.V. | MRUS | Maintain | Buy (N/A) |
|
Details | ||
| 9/9/2021 | Humanigen | HGEN | Maintain | Buy (N/A) |
|
Details | ||
| 8/5/2021 | Intellia Therapeutics | NTLA | Maintain | Buy (N/A) |
|
Details | ||
| 6/28/2021 | Intellia Therapeutics | NTLA | Maintain | Buy (N/A) |
|
Details | ||
| 6/28/2021 | BioAtla Inc. | BCAB | New Coverage | Buy (N/A) |
42.75 (0.17) |
-99.6% | Details | |
| 6/28/2021 | Panbella Therapeutics | PBLA | New Coverage | Buy (N/A) |
3.55 (0.01) |
-99.72% | Details | |
| 6/7/2021 | Merus N.V. | MRUS | Maintain | Buy (N/A) |
|
Details | ||
| 5/7/2021 | Intellia Therapeutics | NTLA | Upgrade | Buy (Neutral) |
71.36 (13.44) |
-81.17% | Details | |
| 5/6/2021 | Bicycle Therapeutics | BCYC | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2021 | Humanigen | HGEN | Maintain | Buy (N/A) |
|
Details | ||
| 3/17/2021 | GT Biopharma Inc. | GTBP | New Coverage | Buy (N/A) |
6.07 (2.87) |
-52.72% | Details | |
| 3/4/2021 | Five Prime Therapeutics | FPRX | Downgrade | Neutral (Buy) |
21.26 (38.00) |
78.74% | Details | |
| 1/19/2021 | Merus N.V. | MRUS | Maintain | Buy (N/A) |
|
Details | ||
| 1/11/2021 | Humanigen | HGEN | Maintain | Buy (N/A) |
|
Details | ||
| 1/6/2021 | Marker Therapeutics | MRKR | Maintain | Neutral (N/A) |
|
Details | ||
| 12/22/2020 | Translate Bio | TBIO | Maintain | Buy (N/A) |
|
Details | ||
| 12/7/2020 | Ayala Pharmaceuticals Inc. | AYLA | New Coverage | Buy (N/A) |
2.47 (0.50) |
-79.76% | Details | |
| 11/11/2020 | Five Prime Therapeutics | FPRX | Upgrade | Buy (Neutral) |
5.34 (21.26) |
298.13% | Details | |
| 10/21/2020 | CRISPR Therapeutics | CRSP | Maintain | Buy (N/A) |
|
Details | ||
| 10/19/2020 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 7/27/2020 | TCR2 Therapeutics | TCRR | Upgrade | Buy (Neutral) |
13.10 (1.48) |
-88.7% | Details | |
| 7/13/2020 | NextCure Inc. | NXTC | New Coverage | Neutral (N/A) |
17.88 (12.39) |
-30.7% | Details | |
| 6/26/2020 | G1 Therapeutics | GTHX | New Coverage | Buy (N/A) |
24.37 (7.15) |
-70.66% | Details | |
| 6/23/2020 | Translate Bio | TBIO | Maintain | Buy (N/A) |
|
Details | ||
| 6/5/2020 | Adaptimmune Therapeutics plc | ADAP | Maintain | Buy (N/A) |
|
Details | ||
| 5/19/2020 | Allogene | ALLO | Upgrade | Buy (Neutral) |
44.91 (2.30) |
-94.88% | Details | |
| 4/22/2020 | Compugen | CGEN | New Coverage | Buy (N/A) |
13.99 (2.08) |
-85.13% | Details | |
| 3/2/2020 | Forty Seven Inc. | FTSV | Downgrade | Neutral (Buy) |
58.00 (95.51) |
64.67% | Details | |
| 3/2/2020 | Forty Seven Inc. | FTSV | Downgrade | Neutral (Buy) |
58.00 (95.51) |
64.67% | Details | |
| 3/2/2020 | NextCure Inc. | NXTC | New Coverage | Buy (N/A) |
41.76 (17.88) |
-57.18% | Details | |
| 2/28/2020 | Five Prime Therapeutics | FPRX | Maintain | Neutral (N/A) |
|
Details | ||
| 12/10/2019 | ArQule | ARQL | Downgrade | Neutral (Buy) |
19.70 (20.00) |
1.52% | Details | |
| 12/4/2019 | Marker Therapeutics | MRKR | Maintain | Buy (N/A) |
|
Details | ||
| 11/19/2019 | CRISPR Therapeutics | CRSP | Maintain | Buy (N/A) |
|
Details | ||
| 11/14/2019 | Bicycle Therapeutics | BCYC | New Coverage | Buy (N/A) |
8.14 (5.19) |
-36.24% | Details | |
| 9/4/2019 | Replimune Group | REPL | New Coverage | Buy (N/A) |
10.38 (15.61) |
50.39% | Details | |
| 9/4/2019 | Atreca Inc. | BCEL | New Coverage | Buy (N/A) |
19.41 (0.09) |
-99.54% | Details | |
| 7/30/2019 | CRISPR Therapeutics | CRSP | Maintain | Buy (N/A) |
|
Details | ||
| 7/16/2019 | Atara Biotherapeutics | ATRA | Maintain | Buy (N/A) |
|
Details | ||
| 6/28/2019 | Merus N.V. | MRUS | New Coverage | Buy (N/A) |
14.23 (90.00) |
532.47% | Details | |
| 6/14/2019 | ArQule | ARQL | Maintain | Buy (N/A) |
|
Details | ||
| 6/10/2019 | Intellia Therapeutics | NTLA | New Coverage | Neutral (N/A) |
14.26 (13.44) |
-5.75% | Details | |
| 6/7/2019 | Fate Therapeutics | FATE | New Coverage | Neutral (N/A) |
19.06 (1.33) |
-93.02% | Details | |
| 6/5/2019 | Allogene | ALLO | New Coverage | Neutral (N/A) |
27.24 (2.30) |
-91.56% | Details | |
| 5/30/2019 | Marker Therapeutics | MRKR | New Coverage | Buy (N/A) |
5.97 (1.38) |
-76.88% | Details | |
| 5/30/2019 | Atara Biotherapeutics | ATRA | New Coverage | Buy (N/A) |
22.33 (5.17) |
-76.85% | Details | |
| 5/29/2019 | Forty Seven Inc. | FTSV | New Coverage | Buy (N/A) |
12.15 (58.00) |
377.37% | Details | |
| 5/29/2019 | Five Prime Therapeutics | FPRX | New Coverage | Neutral (N/A) |
9.05 (38.00) |
319.89% | Details | |
| 5/29/2019 | Corvus Pharmaceuticals | CRVS | New Coverage | Buy (N/A) |
4.03 (15.80) |
292.06% | Details |
